Events

Investival Showcase Virtual w/ Jackie Hunter

External And Internal Convergence - A Cross-Sector Approach To Healthcare’s Biggest Challenges.

Wednesday, November 11 - 14:45 GMT

As health economies face challenges of improving outcomes while lowering cost, among many others, a cross-sector approach to health and care is vital. Alongside new biotechnologies and combination therapeutic approaches has come the rapid expansion of AI in multiple settings, new digital technologies and, importantly, the more tech-savvy and engaged patient, convergence is starting to make meaningful impacts. How is the industry developing new core digital capabilities, alliances, partnerships and innovative ways to drive better outcomes? 

  • In which ways are health and care industry leaders’ driving solutions to healthcare’s biggest challenges through different therapeutics, digital, and device combination approaches? 
  • To what extent and in which ways does external innovation fit into this picture for pharma companies like J&J? 
  • How can the wider industry work towards true and meaningful convergence to improve outcomes? 
  • How can this holistic approach and personalised medicine approaches go hand in hand? 

Panelists:

Melanie Senior, Writer and Analyst (moderator) 

Prabhu Velusami, Senior Director, New Ventures and Transactions, Johnson & Johnson 

Dan Vahdat, CEO, Huma 

Nikolaj Sorensen, CEO, Orexo 

Jackie Hunter, Board Director, BenevolentAI 

Eric Marcotulli, CEO, Elysium Health

Register →


Jackie Hunter
Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.

More Posts

You Might Also Like

News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
News
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022